P.042 Could Live Cell-Based Assay increase the acetylcholine receptor autoantibodies seropositivity in patients with clinical suspicion of myasthenia gravis?

Background: AChR antibodies (Abs) in Myasthnia Gravis (MG) are detected approximately 50% of ocular and 85% generalized MG by the current gold standard radioimmunoprecipitation assay (RIPA). Recently, fixed lived Cell-Based assays (L-CBA) developed. We clinically validated our in-house L-CBA detecting Ab suspected patients. Methods: Between January 2020 April 2022, we assayed 10167 sera for RIPA. also 4349 seronegative above samples anti-MuSK Then 1228 double and/or borderline was assessed Ab. For clinical validation, obtained information on 36 seropositive cases L-CBA. Results: found additional eighty-four The based their final diagnosis, twenty had MG, thirteen 2 not yet diagnosed 1 case not-MG. Conclusions: L- CBA has demonstrated improved sensitivity higher diagnostics performance than allowed diagnosis increased seropositivity (by 7%) patients who were earlier seronegative/borderline